Meta-analysis · people
Abaloparatide, teriparatide beat other drugs on spine BMD in men
Checked against the paper Meta-analysisPublished by PepVault
The takeaway
In men with osteoporosis, abaloparatide was among the top options for spine and femoral neck bone density, but it did not lead on total hip density or on side effects.
- Kind
- Meta-analysis
- Studied in
- People
- Published
- 2025
- Journal
- Front Endocrinol (Lausanne)
What they tested
The team wanted to compare how well and how safely five drug options treat osteoporosis in men: abaloparatide, denosumab, teriparatide, oral bisphosphonates and intravenous (IV) bisphosphonates.
How the study was done
A systematic review and Bayesian network meta-analysis, a method that pools published studies to compare several treatments at once, focused on men with osteoporosis. It compared the five drug options on bone mineral density (BMD, a measure of how dense bones are) and on adverse events (side effects).

What they found
Abaloparatide and teriparatide did significantly better than the other drugs for raising BMD at the lumbar spine (lower back) and the femoral neck (the top of the thigh bone near the hip joint). Oral bisphosphonates did best for total hip BMD, where teriparatide did less well. On safety, teriparatide did best for all adverse events, and oral bisphosphonates did best for lowering severe adverse events.
What it doesn’t show
This study covers men only. It compares the drugs by pooling separate studies rather than testing them side by side in a single trial.
The paper
Chen et al. Efficacy and safety of abaloparatide, denosumab, teriparatide, oral bisphosphonates, and intravenous bisphosphonates in the treatment of male osteoporosis: a systematic review and Bayesian network meta-analysis. Front Endocrinol (Lausanne). 2025.
The compounds
More studies on Abaloparatide
- Abaloparatide: larger hip BMD gains than teriparatide at 24 weeksMeta-analysis · people · 2023
- Abaloparatide raised hip BMD around a virtual hip stem in ACTIVERandomized trial · people · 2024
- Abaloparatide improved hip geometry vs placebo in ACTIVE-JRandomized trial · people · 2023
- Abaloparatide then alendronate: 84% lower vertebral fracture riskRandomized trial · people · 2018
- Abaloparatide: normal bone biopsies after up to 18 months in ACTIVERandomized trial · people · 2017
- Abaloparatide: fewer new vertebral fractures vs placebo in ACTIVERandomized trial · people · 2016
- Every study on Abaloparatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.